Ligand Pharmaceuticals Incorporated
LGND
$104.97
$0.350.34%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -107.73% | 174.52% | 55.18% | 301.89% | 256.33% |
| Total Depreciation and Amortization | -3.51% | -8.29% | -16.02% | -22.80% | -28.91% |
| Total Amortization of Deferred Charges | 32.25% | -0.69% | -44.60% | -59.95% | -68.43% |
| Total Other Non-Cash Items | 757.65% | -94.33% | 4,082.22% | -444.14% | -113.92% |
| Change in Net Operating Assets | 156.26% | -200.93% | -206.43% | -237.42% | -152.38% |
| Cash from Operations | 95.75% | -19.31% | -55.71% | -71.31% | -64.04% |
| Capital Expenditure | 48.28% | 70.85% | 84.39% | 92.16% | 80.35% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 100.00% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -6,420.99% | -1,735.51% | -295.78% | -118.99% | -98.76% |
| Cash from Investing | -1,129.79% | -1,228.32% | -394.43% | -143.13% | -107.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 99.97% | 99.97% | 99.98% | 21.26% | 70.54% |
| Issuance of Common Stock | 357.63% | 204.66% | 135.63% | 447.29% | 594.55% |
| Repurchase of Common Stock | -12.95% | 46.87% | 47.15% | 46.88% | 44.79% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 55.11% | 840.30% | 87.44% | 88.28% | 90.49% |
| Cash from Financing | 262.04% | 216.31% | 126.39% | 55.81% | 78.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 323.80% | 177.99% | -144.49% | -152.40% | -186.53% |